Literature DB >> 2155555

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.

L B Heifets1, P J Lindholm-Levy, M A Flory.   

Abstract

Minimal inhibitory and bactericidal concentrations (MICs and MBCs) of rifampin (RMP), rifabutin (RBT), rifapentine (RPT), CGP-7040, and P-DEA, were determined for 50 M. avium strains in 7H12 liquid medium radiometrically under various pH conditions. Half were isolated from patients with AIDS and the other half from patients without AIDS but with pulmonary disease. The MICs and MBCs were also determined in 7H12 broth for M. tuberculosis strains. The MIC results obtained with M. tuberculosis strains, and the serum peak levels in humans, were used as standards for interpretation of the MICs and MBCs of the rifamycins for M. avium. The bactericidal activity of all rifamycins for M. avium was substantially lower than for M. tuberculosis. The majority of M. avium strains was within the "susceptible" category, e.g., comparable to susceptible M. tuberculosis strains, when tested with CGP-7040 and RPT, and all of them were "moderately susceptible" when tested with P-DEA. On the basis of in vitro bacteriostatic and bactericidal activity, it seems that three agents, RPT, P-DEA, and CGP-7040 have more potential than do RMP and RBT against M. avium disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155555     DOI: 10.1164/ajrccm/141.3.626

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  43 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.

Authors:  A C Keung; R C Owens; M G Eller; S J Weir; D P Nicolau; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  Rapid determination of rifampin resistance in clinical isolates of Mycobacterium tuberculosis by real-time PCR.

Authors:  Tanil Kocagoz; Zeynep Saribas; Alpaslan Alp
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

6.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

Review 7.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Authors:  Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

9.  In vitro activities of new macrolides and rifapentine against Brucella spp.

Authors:  J A García-Rodríguez; J L Muñoz Bellido; M J Fresnadillo; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

Authors:  J V Brooks; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.